Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2311 to 2325 of 7681 results

  1. Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer ID6339

    In development [GID-TA11432] Expected publication date: 02 July 2025

    Technology appraisal guidance
    In development

  2. Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]

    In development [GID-TA10990] Expected publication date: 25 June 2025

    Technology appraisal guidance
    In development

  3. Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (Review of TA762) [ID6336]

    In development [GID-TA11514] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer [ID6220]

    In development [GID-TA11197] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Resminostat for maintenance treatment of advanced mycosis fungoides or Sézary syndrome ID6478

    Awaiting development [GID-TA11606] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Dupilumab for treating bullous pemphigoid [ID6479]

    Awaiting development [GID-TA11615] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Pulsed field ablation for atrial fibrillation

    In development [GID-IPG10267] Expected publication date: 09 July 2025

    Interventional procedures guidance
    In development

  8. Laparoscopic insertion of a non-active implant for gastro-oesophageal reflux disease

    In development [GID-IPG10345] Expected publication date: 17 April 2025

    Interventional procedures guidance
    In development

  9. Drug-eluting coronary stents for treating coronary artery disease: late-stage assessment

    In development [GID-HTE10039] Expected publication date: 12 May 2025

    Health technology evaluations
    In development

  10. Gambling-related harms: identification, assessment and management

    In development [GID-NG10210] Expected publication date: TBC

    NICE guideline
    In development

  11. Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6212

    In development [GID-TA11203] Expected publication date: 05 March 2025

    Technology appraisal guidance
    In development

  12. Tegaderm CHG securement dressing for vascular access sites in critically ill adults (MTG25)

    Evidence-based recommendations on The 3M Tegaderm CHG IV securement dressing for central venous and arterial catheter insertion sites.

    Medical technologies guidance
    Last updated
    18 September 2019
    View recommendations

    Sections for MTG25

  13. Senza spinal cord stimulation system for delivering HF10 therapy to treat chronic neuropathic pain (MTG41)

    Evidence-based recommendations on the Senza spinal cord stimulation system for delivering HF10 therapy to treat chronic neuropathic pain.

    Medical technologies guidance
    Published
    23 January 2019
    View recommendations

    Sections for MTG41

  14. UrgoStart for treating diabetic foot ulcers and leg ulcers (MTG42)

    Evidence-based recommendations on UrgoStart for treating diabetic foot ulcers and leg ulcers.

    Medical technologies guidance
    Last updated
    4 April 2023
    View recommendations

    Sections for MTG42

  15. PICO negative pressure wound dressings for closed surgical incisions (MTG43)

    Evidence-based recommendations on PICO negative pressure wound dressings for closed surgical incisions.

    Medical technologies guidance
    Last updated
    6 August 2019
    View recommendations

    Sections for MTG43